Open Access Repository
Bertilimumab (Cambridge Antibody Technology Group)
Download Statistics
Downloads
Downloads per month over past year
Ding, C, Li, J and Zhang, X 2004
, 'Bertilimumab (Cambridge Antibody Technology Group)'
, Current Opinion in Investigational Drugs, vol. 5, no. 11
, pp. 1213-1219
.
![]() |
PDF
bertilimumab.pdf | Request a copy Full text restricted Available under University of Tasmania Standard License. |
Official URL: http://www.biomedcentral.com/1472-4472/5?issue=11
Abstract
Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.
Item Type: | Article |
---|---|
Authors/Creators: | Ding, C and Li, J and Zhang, X |
Journal or Publication Title: | Current Opinion in Investigational Drugs |
ISSN: | 1472-4472 |
Item Statistics: | View statistics for this item |
Actions (login required)
![]() |
Item Control Page |